• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Brian Orelli

Brian Orelli

Articles

ARTICLES

Biotechs Hold Less Cash But Lean Ops Increase Runways

May 14, 2012
By Brian Orelli
Cash is often biotech's most precious resource, but when a recession hits and capital markets seize up, it can be hard to come by.
Read More

To Partner or Not to Partner? That Is the Hep C Question

May 7, 2012
By Brian Orelli
Data presented at the 2012 International Liver Congress of the European Association for the Study of the Liver last month showed Gilead Sciences Inc.'s nuc drug GS-7977 works well with Bristol-Myers Squibb Co.'s NS5A inhibitor daclatasvir.
Read More

Pathways, Not Genes, Most Important for Cancer Drugs

April 30, 2012
By Brian Orelli
Drugs act on proteins, so it follows that protein activity would be most important in determining which patients are given a targeted cancer drug.
Read More

Permanent Capital Focuses Safeguard's Investing Habits

April 23, 2012
By Brian Orelli
In conjunction with Eli Lilly and Co.'s recent FDA approval of Amyvid (florbetapir), Safeguard Scientifics Inc. received a $5.6 million earn-out payment from its investment in Avid Radiopharmaceuticals Inc. before Lilly purchased the biotech.
Read More

A Clean Hit on the Target: In the Lung, Less Is More

April 16, 2012
By Brian Orelli
Inhaled asthma and chronic obstructive pulmonary disease (COPD) drugs act at the lung to improve breathing, but at supraoptimal doses, the drugs end up elsewhere in the body, potentially leading to undesirable side effects.
Read More

Biomarkers Helpful but Not Cornucopia for Heart Drugs

April 9, 2012
By Brian Orelli
Last month, Anthera Pharmaceuticals Inc.'s Phase III VISTA-16 trial testing varespladib in acute coronary syndrome (ACS) patients was stopped for futility, a surprise considering the robust changes in biomarkers seen in the Phase II trial.
Read More

Delta Dental Funds Startup: Gives Advice, Expects Return

March 26, 2012
By Brian Orelli
C3 Jian Inc. has found funding from an unusual place: Three Delta Dental member companies contributed $30 million to help the biotech develop C16G2, a peptide drug targeting the bacteria that cause dental cavities, and the rest of its oral health pipeline.
Read More

CBER Pathway for Allogeneic Product Approval Emerges

March 19, 2012
By Brian Orelli
In 1998, Organogenesis Inc. received approval for its first allogeneic product, Apligraf, from the FDA's Center for Devices and Radiological Health (CDRH).
Read More

As Dacogen Rejected, Firms Define Unmet Need for AML

March 9, 2012
By Brian Orelli

Last week, Eisai Co. Ltd. and Astex Pharmaceuticals Inc. received a complete response letter for their request to expand the use of Dacogen (decitabine), which already is approved for myelodysplastic syndromes, into acute myeloid leukemia (AML) patients 65 years of age and older.


Read More

Biotechs Take Heed: Docs, Investors Predict Accurately

March 5, 2012
By Brian Orelli
Correctly predicting the future is a necessary but difficult task for biotech executives. Making accurate forecasts about demographic trends, clinical data, regulatory decisions, competition, and prescription trends can guide where to allocate limited capital and even the timing on when to raise more.
Read More
View All Articles by Brian Orelli

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 12, 2025.
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • Digital globe illustrating pharma trade, tariffs

    Navigating the Trump tariffs, part two: Amgen, Biogen, others

    BioWorld
    As biopharma companies continue to roll out their first-quarter  earnings, Trump administration tariffs remain at the top of investors’ minds. While executives...
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe